Boltwood Capital Management Sells 3,688 Shares of Pfizer Inc. (NYSE:PFE)

Boltwood Capital Management cut its position in shares of Pfizer Inc. (NYSE:PFE) by 6.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 56,649 shares of the biopharmaceutical company’s stock after selling 3,688 shares during the period. Boltwood Capital Management’s holdings in Pfizer were worth $1,435,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Tallon Kerry Patrick purchased a new stake in Pfizer in the 4th quarter worth approximately $509,000. Brighton Jones LLC lifted its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. Alliance Wealth Advisors LLC UT raised its stake in Pfizer by 5.6% during the fourth quarter. Alliance Wealth Advisors LLC UT now owns 12,571 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 669 shares during the last quarter. Finally, Old North State Wealth Management LLC raised its stake in Pfizer by 23.6% during the fourth quarter. Old North State Wealth Management LLC now owns 79,441 shares of the biopharmaceutical company’s stock valued at $2,109,000 after buying an additional 15,194 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of Pfizer stock opened at $23.42 on Thursday. The stock has a 50 day moving average of $23.02 and a 200 day moving average of $25.02. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a market cap of $133.15 billion, a PE ratio of 16.61, a PEG ratio of 0.64 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the business posted $0.82 earnings per share. The company’s quarterly revenue was down 7.8% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.34%. Pfizer’s payout ratio is 124.64%.

Analyst Upgrades and Downgrades

A number of analysts have commented on PFE shares. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.